The positive impact of the novel agents on the prognosis of multiple myeloma has been demonstrated in several phase III clinical trials. However, clinical trials may not reflect the real life situation because of selection bias.

Study aim
Our aim was to study overall survival in a consecutive cohort of patients exposed to novel agents.
Patient population and methods
A total of 63 consecutive symptomatic myeloma patients diagnosed and treated in the department of Clinical Hematology in UZ Brussel between January 1st 2007 and December 31st 2011, were included. Of these, 59 received at least one line of anti-myeloma treatment including novel agents. Patient characteristics: M/F (46%/54%); ISS stage I (47%), II (31%) and III (22%); median age at diagnosis: 66 years; creatinine clearance Results
First-line treatment was thalidomide-based in 44%, bortezomib-based in 46% and lenalidomide-based in 3% of cases. Only 19 (33%) patients were included in clinical trials. With a median follow-up time of 24 months, the median overall survival (OS) time for the total group (n=63) was 41 months with a 3-year estimated OS probability of 60%. The mean OS of the 59 treated patients was 48.2 (40.2 - 56.1) months with a 3-year OS probability of 64%. The mean OS of treated patients stratified according to ISS stage was 51.1, 40.6 and 23.8 months for ISS groups I, II and III, respectively (I vs. III, p
Our data confirm the positive impact of novel agents on OS of myeloma patients in a real-life single center setting. The impact is more apparent for patients eligible for ASCT. The prognostic role of the ISS staging system is maintained in the era of the novel agents.
Original languageEnglish
Pages (from-to)28-29
Number of pages2
JournalBelgian Journal of Hematology
Issue number2013
Publication statusPublished - 24 Jan 2013

    Research areas

  • myeloma

ID: 2260340